Evidence map›Paper›PMID 24492308›Full record

ArticlemAbs

3D modeling and characterization of the human CD115 monoclonal antibody H27K15 epitope and design of a chimeric CD115 target.

Benoît Grellier, Fabrice Le Pogam, Marc Vitorino, Jean-Philippe Starck, Michel Geist, Vanessa Duong, Hélène Haegel, Thierry Menguy, Jean-Yves Bonnefoy, Jean-Baptiste Marchand and 1 more

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Benoît GrellierTRANSGENE S.A.; Illkirch-Graffenstade, France.
Fabrice Le PogamTRANSGENE S.A.; Illkirch-Graffenstade, France.
Marc VitorinoNMRTEC S.A.S.; Illkirch-Graffenstaden, France.
Jean-Philippe StarckNMRTEC S.A.S.; Illkirch-Graffenstaden, France.
Michel GeistTRANSGENE S.A.; Illkirch-Graffenstade, France.
Vanessa DuongTRANSGENE S.A.; Illkirch-Graffenstade, France.
Hélène HaegelTRANSGENE S.A.; Illkirch-Graffenstade, France.
Thierry MenguyTRANSGENE S.A.; Illkirch-Graffenstade, France.
Jean-Yves BonnefoyTRANSGENE S.A.; Illkirch-Graffenstade, France; ElsaLys Biotech; Illkirch-Graffenstaden, France.
Jean-Baptiste MarchandTRANSGENE S.A.; Illkirch-Graffenstade, France.
Philippe AncianTRANSGENE S.A.; Illkirch-Graffenstade, France.
Transgene (France) · FRSouth Bend Museum of Art · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The humanized monoclonal antibody H27K15 specifically targets human CD115, a type III tyrosine kinase receptor involved in multiple cancers and inflammatory diseases. Binding of H27K15 to hCD115 expressing cells inhibits the functional effect of colony-stimulating factor-1 (CSF-1), in a non-competitive manner. Both homology modeling and docking programs were used here to model the human CD115 extracellular domains, the H27K15 variable region and their interaction. The resulting predicted H27K15 epitope includes mainly the D1 domain in the N-terminal extracellular region of CD115 and some residues of the D2 domain. Sequence alignment with the non-binding murine CD115, enzyme-linked immunosorbent assay, nuclear magnetic resonance spectroscopy and affinity measurements by quartz crystal microbalance revealed critical residues of this epitope that are essential for H27K15 binding. A combination of computational simulations and biochemical experiments led to the design of a chimeric CD115 carrying the human epitope of H27K15 in a murine CD115 backbone that is able to bind both H27K15 as well as the murine ligands CSF-1 and IL-34. These results provide new possibilities to minutely study the functional effects of H27K15 in a transgenic mouse that would express this chimeric molecule.

Indexed as

AnimalsAntibodies, MonoclonalComputational BiologyEnzyme-Linked Immunosorbent AssayEpitopesHumansImmunoglobulin Variable RegionInterleukinsMacrophage Colony-Stimulating FactorMiceModels, ChemicalProtein BindingReceptor, Macrophage Colony-Stimulating FactorRecombinant Fusion ProteinsSequence AlignmentAntibodies, MonoclonalEpitopesImmunoglobulin Variable Regioninterleukin-34, mouseInterleukinsMacrophage Colony-Stimulating FactorReceptor, Macrophage Colony-Stimulating FactorRecombinant Fusion ProteinsCD115CSF-1epitope mappinghomology modelingIL-34NMRprotein-protein dockingquartz crystal microbalance

Identifiers

PMID24492308
PMCPMC3984341
OpenAlexW1965617770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.